- Home
- LRE vs EVAX Comparison
LRE vs EVAX Comparison
Compare LRE & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- EVAX
- Stock Information
- Founded
- LRE 2001
- EVAX 2008
- Country
- LRE Japan
- EVAX Denmark
- Employees
- LRE N/A
- EVAX N/A
- Industry
- LRE
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LRE
- EVAX Health Care
- Exchange
- LRE Nasdaq
- EVAX Nasdaq
- Market Cap
- LRE 19.2M
- EVAX 17.6M
- IPO Year
- LRE 2023
- EVAX 2021
- Fundamental
- Price
- LRE $1.51
- EVAX $2.95
- Analyst Decision
- LRE
- EVAX Strong Buy
- Analyst Count
- LRE 0
- EVAX 2
- Target Price
- LRE N/A
- EVAX $11.00
- AVG Volume (30 Days)
- LRE 7.4K
- EVAX 98.5K
- Earning Date
- LRE 01-01-0001
- EVAX 08-14-2024
- Dividend Yield
- LRE N/A
- EVAX N/A
- EPS Growth
- LRE N/A
- EVAX N/A
- EPS
- LRE 0.25
- EVAX N/A
- Revenue
- LRE $118,414,146.00
- EVAX $278,000.00
- Revenue This Year
- LRE N/A
- EVAX $495.23
- Revenue Next Year
- LRE N/A
- EVAX $0.94
- P/E Ratio
- LRE $6.00
- EVAX N/A
- Revenue Growth
- LRE 14.65
- EVAX N/A
- 52 Week Low
- LRE $1.19
- EVAX $2.26
- 52 Week High
- LRE $13.76
- EVAX $13.61
- Technical
- Relative Strength Index (RSI)
- LRE 48.23
- EVAX 46.84
- Support Level
- LRE $1.51
- EVAX $2.81
- Resistance Level
- LRE $1.63
- EVAX $3.22
- Average True Range (ATR)
- LRE 0.10
- EVAX 0.25
- MACD
- LRE 0.03
- EVAX -0.01
- Stochastic Oscillator
- LRE 65.79
- EVAX 30.27
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo and Kanagawa prefecture. It operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. It generates revenue from developing and selling single-family homes and condominiums. The company's primary and sole operating segment is real estate sales.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.